The estimation of health state utility values in rare diseases: overview of existing techniques

There are several techniques for estimating health state utility values, each of which presents pros and cons in the context of rare diseases (RDs). Direct approaches (e.g. standard gamble and time trade-off) may be too demanding for patients with RDs, since most of them affect young children or cause cognitive impairment. The alternatives are using “vignettes” that describe hypothetical health states for the general public, which may not reflect the heterogeneous manifestations of RDs, or multi-attribute utility instruments (i.e. indirect techniques), such as EQ-5D, which may be less sensitive in capturing the specificities of RDs. The “rule of rescue” approach is a promising alternative in RDs, since it prioritizes identifiable patients with life-threatening or disabling conditions. However, it raises measurement challenges and ethical issues. Furthermore, the literature reports on relevant implications of choosing a technique over others for health technology assessment, which should be considered in relation to individual RDs.

[1]  M. Drummond,et al.  ‘Mapping’ Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases , 2020, PharmacoEconomics.

[2]  D. Feeny,et al.  Characterizing health state utilities associated with Duchenne muscular dystrophy: a systematic review , 2019, Quality of Life Research.

[3]  P. Kanavos,et al.  Health related quality of life aspects not captured by EQ-5D-5L: Results from an international survey of patients. , 2019, Health policy.

[4]  L. Prosser,et al.  Health utilities and parental quality of life effects for three rare conditions tested in newborns , 2019, Journal of Patient-Reported Outcomes.

[5]  B. Arnould,et al.  Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing’s syndrome , 2018, Orphanet Journal of Rare Diseases.

[6]  A. Slade,et al.  Patient reported outcome measures in rare diseases: a narrative review , 2018, Orphanet Journal of Rare Diseases.

[7]  A. Olaye,et al.  Economic Modeling Considerations for Rare Diseases. , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  J. Brazier,et al.  Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies , 2017, PharmacoEconomics.

[9]  John Brazier,et al.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment , 2017, PharmacoEconomics.

[10]  J. Brazier,et al.  A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models , 2017, PharmacoEconomics.

[11]  N. Weinstein,et al.  Orphan Drugs In The Uk, Do They Meet The Nice Highly Specialised Technology Threshold? , 2017 .

[12]  É. Silva,et al.  Avaliação econômica no âmbito das doenças raras: isto é possível? , 2015 .

[13]  Donna Rowen,et al.  Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  J. Brazier,et al.  Using a discrete choice experiment to estimate health state utility values. , 2012, Journal of health economics.

[15]  C. Lind,et al.  Neurotrauma and the rule of rescue , 2011, Journal of Medical Ethics.

[16]  J. Brazier,et al.  NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet] , 2011 .

[17]  David T Arnold,et al.  Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis , 2009, BMJ : British Medical Journal.

[18]  R. Hays,et al.  Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis , 2007, Quality of Life Research.

[19]  D. Hughes,et al.  Drugs for exceptionally rare diseases: do they deserve special status for funding? , 2005, QJM : monthly journal of the Association of Physicians.

[20]  M. Wallace,et al.  Assessment of Health State Utilities and Quality of Life in Patients With Malignant Esophageal Dysphagia , 2004, American Journal of Gastroenterology.

[21]  P. Leigh,et al.  Patients' health-related quality-of-life and health state values for motor neurone disease/amyotrophic lateral sclerosis , 2003, Quality of Life Research.

[22]  Jeff Richardson,et al.  The rule of rescue. , 2003, Social science & medicine.

[23]  E. Nord The Person-trade-off Approach to Valuing Health Care Programs , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.